                         SEQUENCE LISTING

<110>  F. Hoffmann-La Roche AG
       Hoffmann-La Roche Inc.
 
<120>  Peptidic linker with reduced post-translational modification

<130>  P34815-WO

<150>  EP18176698.1
<151>  2018-06-08

<160>  23    

<170>  PatentIn version 3.5

<210>  1
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GnSGmX1


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=G or GG or GGG or GGGG

<220>
<221>  CHAIN
<222>  (3)..(3)
<223>  X=GGG or GGGG or GGGGG

<220>
<221>  SITE
<222>  (4)..(4)

<220>
<221>  SITE
<222>  (4)..(4)
<223>  X=any amino acid residue except for serine, threonine and proline

<400>  1

Xaa Ser Xaa Xaa 
1               


<210>  2
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GnSGmX1X2X3


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=G or GG or GGG or GGGG

<220>
<221>  CHAIN
<222>  (3)..(3)
<223>  X=GGG or GGGG or GGGGG

<220>
<221>  SITE
<222>  (4)..(4)
<223>  X=any amino acid residue except for serine, threonine and proline

<220>
<221>  CHAIN
<222>  (5)..(6)
<223>  X=any amino acid residue

<400>  2

Xaa Ser Xaa Xaa Xaa Xaa 
1               5       


<210>  3
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GpSGnSGmX1X2X3


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=GGG or GGGG

<220>
<221>  CHAIN
<222>  (3)..(3)
<223>  X=GGG or GGGG

<220>
<221>  CHAIN
<222>  (5)..(5)
<223>  X=GGG or GGGG or GGGGG

<220>
<221>  SITE
<222>  (6)..(6)
<223>  X=any amino acid residue except for serine, threonine and proline

<220>
<221>  CHAIN
<222>  (7)..(8)
<223>  X=any amino acid residue

<400>  3

Xaa Ser Xaa Ser Xaa Xaa Xaa Xaa 
1               5               


<210>  4
<211>  2
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GyX1


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=Gn with n=3 to 25

<220>
<221>  SITE
<222>  (2)..(2)
<223>  X=any amino acid residue except for serine, threonine and proline

<400>  4

Xaa Xaa 
1       


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GyX1X2X3


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=Gn with n= 3 to 25

<220>
<221>  SITE
<222>  (2)..(2)
<223>  X=any amino acid residue except for serine, threonine and proline

<220>
<221>  CHAIN
<222>  (3)..(4)
<223>  X=any amino acid residue

<400>  5

Xaa Xaa Xaa Xaa 
1               


<210>  6
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GnSGm(S,T,P)X2X3


<220>
<221>  CHAIN
<222>  (1)..(1)
<223>  X=G or GG or GGG or GGGG

<220>
<221>  CHAIN
<222>  (3)..(3)
<223>  X=GGG or GGGG or GGGGG

<220>
<221>  SITE
<222>  (4)..(4)
<223>  X=any amino acid residue except for serine, threonine and proline

<220>
<221>  SITE
<222>  (4)..(4)
<223>  X=serine, threonine or proline

<220>
<221>  CHAIN
<222>  (5)..(6)
<223>  X=any amino acid residue

<400>  6

Xaa Ser Xaa Xaa Xaa Xaa 
1               5       


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  X9GGGGSGGGGSR


<220>
<221>  SITE
<222>  (1)..(1)
<223>  X=N-terminal amino acid residue of first non-immunoglobulin 
       polypeptide

<220>
<221>  MOD_RES
<222>  (11)..(11)
<223>  phospho-serine PHOSPHORYLATION

<400>  7

Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  X9GGGGSGGGGpSR


<220>
<221>  SITE
<222>  (1)..(1)
<223>  X=N-terminal amino acid residue of first non-immunoglobulin 
       polypeptide

<220>
<221>  SITE
<222>  (11)..(11)
<223>  Xaa can be any naturally occurring amino acid

<400>  8

Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Xaa Arg 
1               5                   10          


<210>  9
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  X9GGGGSGGGGSREX3


<220>
<221>  SITE
<222>  (1)..(1)
<223>  X=N-terminal amino acid residue of first non-immunoglobulin 
       polypeptide

<220>
<221>  SITE
<222>  (14)..(14)
<223>  X=N-terminal amino acid residue of first non-immunoglobulin 
       polypeptide

<400>  9

Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Glu Xaa 
1               5                   10                  


<210>  10
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SLSLSPGGGGGSGGGGSGGGGSGGGGSIQMT

<400>  10

Ser Leu Ser Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly 
1               5                   10                  15      


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile Gln Met Thr 
            20                  25                  30      


<210>  11
<211>  47
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LC3-F fragment

<400>  11

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
1               5                   10                  15      


Gly Gly Ser Gly Gly Gly Gly Thr Cys Pro Pro Cys Pro Ala Pro Glu 
            20                  25                  30          


Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
        35                  40                  45          


<210>  12
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LC3-F tryptic digest with OpeRATOR protease

<400>  12

Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 
1               5                   10                  15      


Phe Leu Phe Pro Pro Lys Pro 
            20              


<210>  13
<211>  49
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  LC3-F tryptic digest without OpeRATOR protease


<220>
<221>  CHAIN
<222>  (1)..(2)
<223>  Xaa can be any naturally occurring amino acid

<400>  13

Xaa Xaa Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15      


Gly Gly Gly Gly Ser Gly Gly Gly Gly Thr Cys Pro Pro Cys Pro Ala 
            20                  25                  30          


Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 
        35                  40                  45              


Lys 
    


<210>  14
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HC4-F fragment

<400>  14

Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Thr 
1               5                   10              


<210>  15
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  X8LGGGGSGGGGS(+Fucose)RT


<220>
<221>  SITE
<222>  (1)..(1)
<223>  C-terminal amino acid residue of domain 1

<220>
<221>  MOD_RES
<222>  (12)..(12)
<223>  FUCOSYLATED

<400>  15

Xaa Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Xaa Arg Thr 
1               5                   10                  


<210>  16
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  repetitive unit GGGS

<400>  16

Gly Gly Gly Ser 
1               


<210>  17
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  repetitive unit GGGGS

<400>  17

Gly Gly Gly Gly Ser 
1               5   


<210>  18
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGGP linker

<400>  18

Gly Gly Gly Gly Pro 
1               5   


<210>  19
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGGSGGGGSRE-peptide fragment

<400>  19

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Glu 
1               5                   10          


<210>  20
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGGSGGGGSRT-peptide fragment

<400>  20

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Arg Thr 
1               5                   10          


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGSGGGS

<400>  21

Gly Gly Gly Ser Gly Gly Gly Ser 
1               5               


<210>  22
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGGSGGGGS

<400>  22

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10  


<210>  23
<211>  34
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GGGSGGGGSGGGGSGGGGSGGGGCPPC-peptide fragment

<400>  23

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Cys Pro 
            20                  25                  30          


Pro Cys 
        


